Charles Schwab’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.14M | Sell |
491,709
-55,419
| -10% | -$128K | ﹤0.01% | 2861 |
|
|
2025
Q1 | $761K | Buy |
547,128
+72,871
| +15% | +$101K | ﹤0.01% | 2940 |
|
|
2024
Q4 | $820K | Buy |
474,257
+11,390
| +2% | +$19.7K | ﹤0.01% | 2974 |
|
|
2024
Q3 | $930K | Buy |
462,867
+33,123
| +8% | +$66.6K | ﹤0.01% | 2938 |
|
|
2024
Q2 | $963K | Buy |
429,744
+378,282
| +735% | +$847K | ﹤0.01% | 2950 |
|
|
2024
Q1 | $148K | Buy |
51,462
+35,322
| +219% | +$101K | ﹤0.01% | 3268 |
|
|
2023
Q4 | $28.6K | Hold |
16,140
| – | – | ﹤0.01% | 3453 |
|
|
2023
Q3 | $51K | Hold |
16,140
| – | – | ﹤0.01% | 3406 |
|
|
2023
Q2 | $10.7K | Hold |
16,140
| – | – | ﹤0.01% | 3594 |
|
|
2023
Q1 | $12.9K | Hold |
16,140
| – | – | ﹤0.01% | 3531 |
|
|
2022
Q4 | $36.5K | Hold |
16,140
| – | – | ﹤0.01% | 3421 |
|
|
2022
Q3 | $32K | Sell |
16,140
-74,571
| -82% | -$148K | ﹤0.01% | 3416 |
|
|
2022
Q2 | $338K | Sell |
90,711
-74,634
| -45% | -$278K | ﹤0.01% | 3175 |
|
|
2022
Q1 | $1.08M | Buy |
165,345
+2,785
| +2% | +$18.2K | ﹤0.01% | 2819 |
|
|
2021
Q4 | $1.89M | Buy |
162,560
+4,153
| +3% | +$48.4K | ﹤0.01% | 2718 |
|
|
2021
Q3 | $2.95M | Buy |
158,407
+71,377
| +82% | +$1.33M | ﹤0.01% | 2608 |
|
|
2021
Q2 | $1.85M | Buy |
87,030
+28,787
| +49% | +$611K | ﹤0.01% | 2744 |
|
|
2021
Q1 | $1.18M | Buy |
58,243
+6,011
| +12% | +$122K | ﹤0.01% | 2798 |
|
|
2020
Q4 | $1.39M | Buy |
+52,232
| New | +$1.39M | ﹤0.01% | 2685 |
|